MedTrace Logo

Tolerance Study of the Dietary Supplement Valedia

NCT02790489 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2016-08-09

No results posted yet for this study

Summary

The objectives of this clinical study are to determine the tolerance of dietary supplement Valedia (blend of plant extracts) through the evaluation of several parameters :

* Various blood biological parameters for tolerance (preprandial): blood glucose, insulin, fructosamine, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, oxidized LDL, us-CRP, creatinine, ASAT, ALAT, gGT, phosphatase alcaline, bilirubine, urea.
* Urinary parameters: urea, creatinine.
* Hemodynamic parameters: heart rate and blood pressure.
* Cardiac function: ECG.
* Weight.

Conditions

Interventions

DIETARY_SUPPLEMENT

Valedia

Sponsors & Collaborators

  • Centre d'Investigation Clinique INSERM 501, Clermont-Ferrand, France

    collaborator UNKNOWN

  • Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques

    collaborator OTHER

  • Valbiotis

    lead INDUSTRY

Principal Investigators

  • Sébastien L Peltier, PhD · Valbiotis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02790489 on ClinicalTrials.gov